Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance

PLoS Pathogens

Volumn 14, Issue 11, 2018, Pages

  Pervolaraki, Kalliopi ^a,b   Rastgou Talemi, Soheil ^b,c   Albrecht, Dorothee ^a   Bormann, Felix ^b   Bamford, Connor ^d   Mendoza, Juan L ^e   Garcia, K Christopher ^e   McLauchlan, John ^d   Höfer, Thomas ^b,c   Stanifer, Megan L ^a   Boulant, Steeve ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; COMPLEMENTARY DNA; GAMMA INTERFERON RECEPTOR 1; INTERFERON; INTERFERON GAMMA 2; INTERFERON GAMMA 3; INTERFERON RECEPTOR; INTERFERON STIMULATED GENE FACTOR 1; INTERFERON STIMULATED GENE FACTOR 3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; INTERFERON TYPE III; INTERLEUKIN DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; COLON CARCINOMA CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; EC90; EXPRESSION VECTOR; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERFERON STIMULATED GENE; KINETICS; LUCIFERASE ASSAY; MATHEMATICAL MODEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; VALIDATION PROCESS; VIRUS REPLICATION; WESTERN BLOTTING; CELL LINE; DRUG EFFECT; EPITHELIUM CELL; GENETICS; INTESTINE MUCOSA; METABOLISM;

ANTIVIRAL AGENTS; CELL LINE; EPITHELIAL CELLS; HUMANS; INTERFERON TYPE I; INTERFERONS; INTERLEUKINS; INTESTINAL MUCOSA; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION;

EID: 85058094529     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1007420     Document Type: Article

References (71)

1. Takeuchi O, Akira S, Innate immunity to virus infection. 2009;227:75–86
2. Kawai T, Akira S, Innate immune recognition of viral infection. Nat Immunol. 2006;7(2):131–7. doi: 10.1038/ni1303 pmid: 16424890
3. Koyama S, Ishii KJ, Coban C, Akira S, Innate immune response to viral infection. Cytokine. 2008;43(3):336–41. doi: 10.1016/j.cyto.2008.07.009 pmid: 18694646
4. Kotenko S V, Gallagher G, Baurin V V, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77. doi: 10.1038/ni875 pmid: 12483210
5. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63–8. doi: 10.1038/ni873 pmid: 12469119
6. Sommereyns C, Paul S, Staeheli P, Michiels T, IFN-lambda (IFN-??) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4(3):1–12
7. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010;84(11):5670–7. doi: 10.1128/JVI.00272-10 pmid: 20335250
8. Donnelly RP, Kotenko S V, Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 2010;30(8):555–64. doi: 10.1089/jir.2010.0078 pmid: 20712453
9. Durbin RK, Kotenko S V, Durbin JE, Interferon induction and function at the mucosal surface. Immunol Rev. 2013;255(1):25–39. doi: 10.1111/imr.12101 pmid: 23947345
10. Pott J, Mahlakõiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A. 2011;108(19):7944–9. doi: 10.1073/pnas.1100552108 pmid: 21518880
11. Mahlakõiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P, Leukocyte-Derived IFN-α/β and Epithelial IFN-λ Constitute a Compartmentalized Mucosal Defense System that Restricts Enteric Virus Infections. PLoS Pathog. 2015;11(4):1–19
12. Lin J Da, Feng N, Sen A, Balan M, Tseng HC, McElrath C, et al. Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections. PLoS Pathog. 2016;12(4):1–29
13. Baldridge MT, Nice TJ, McCune BT, Yokoyama CC, Kambal A, Wheadon M, et al. Commensal microbes and interferon-lambda determine persistence of enteric murine norovirus infection_supplemental data. Science. 2014;3(November):1–9
14. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, et al. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science (80-). 2015;347(6219):269–73
15. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark P a B, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–6. doi: 10.1038/nm1462 pmid: 16906156
16. Baños-Lara MDR, Harvey L, Mendoza A, Simms D, Chouljenko VN, Wakamatsu N, et al. Impact and regulation of lambda interferon response in human metapneumovirus infection. J Virol. 2015;89(1):730–42. doi: 10.1128/JVI.02897-14 pmid: 25355870
17. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, et al. Type I and Type III Interferons Drive Redundant Amplification Loops to Induce a Transcriptional Signature in Influenza-Infected Airway Epithelia. PLoS Pathog. 2013;9(11)
18. Jewell N a, Cline T, Mertz SE, Smirnov S V, Flano E, Schindler C, et al. Interferon-{lambda} is the predominant interferon induced by influenza A virus infection in vivo. J Virol. 2010;84(21):11515–22. doi: 10.1128/JVI.01703-09 pmid: 20739515
19. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An Important Role for Type III Interferon (IFN- /IL-28) in TLR-Induced Antiviral Activity. J Immunol. 2008;180(4):2474–85. pmid: 18250457
20. Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M, et al. Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness. Immunity. 2017;46(5):875–890.e6. doi: 10.1016/j.immuni.2017.04.025 pmid: 28514692
21. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko S V, Macdonald MR, et al. Interferons ?? and ?? Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics. Gastroenterology. 2006;131(6):1887–98. doi: 10.1053/j.gastro.2006.09.052 pmid: 17087946
22. Voigt E a., Yin J, Kinetic Differences and Synergistic Antiviral Effects Between Type I and Type III Interferon Signaling Indicate Pathway Independence. J Interf Cytokine Res. 2015;0(0):150504080007003
23. Kohli A, Zhang X, Yang J, Russell RS, Donnelly RP, Sheikh F, et al. Distinct and overlapping genomic profiles and antiviral effects of Interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cells. J Viral Hepat. 2012Dec;19(12):843–53. doi: 10.1111/j.1365-2893.2012.01610.x pmid: 23121362
24. Pervolaraki K, Stanifer ML, Münchau S, Renn LA, Albrecht D, Kurzhals S, et al. Type I and type III interferons display different dependency on mitogen-activated protein kinases to mount an antiviral state in the human gut. Front Immunol. 2017;8(APR):1–16
25. Jilg N, Lin W, Hong J, Schaefer E a., Wolski D, Meixong J, et al. Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology. 2014;59(4):1250–61. doi: 10.1002/hep.26653 pmid: 23913866
26. Bolen CR, Ding S, Robek MD, Kleinstein SH, Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology. 2014;59(4):1262–72. doi: 10.1002/hep.26657 pmid: 23929627
27. Novatt H, Theisen TC, Massie T, Massie T, Simonyan V, in Response to Interferon b and Interferon l 1. 2016;36(10):589–98
28. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R, Type III Interferon (IFN) Induces a Type I IFN-Like Response in a Restricted Subset of Cells through Signaling Pathways Involving both the Jak-STAT Pathway and the Mitogen-Activated Protein Kinases. J Virol. 2007;81(14):7749–58. doi: 10.1128/JVI.02438-06 pmid: 17507495
29. Alase AA, El-Sherbiny YM, Vital EM, Tobin DJ, Turner NA, Wittmann M, IFNλ stimulates MxA production in human dermal fibroblasts via a MAPK-dependent STAT1-independent mechanism. J Invest Dermatol. 2015;135(12):2935–43. doi: 10.1038/jid.2015.317 pmid: 26288353
30. Davidson S, Mccabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, et al. IFN k is a potent anti-influenza therapeutic without the inflammatory side effects of IFN a treatment. 2016;8(9):1099–112
31. Broggi A, Tan Y, Granucci F, Zanoni I, IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat Immunol. 2017;18(10):1084–93. doi: 10.1038/ni.3821 pmid: 28846084
32. Mendoza JL, Schneider WM, Hoffmann H, Jong YP De, Rice CM, Garcia KC, et al. The IFN- l -IFN- l R1-IL-10R b Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity Article The IFN- l -IFN- l R1-IL-10R b Complex Reveals Structural Features Underlying. Immunity. 2017;46(3):379–92. doi: 10.1016/j.immuni.2017.02.017 pmid: 28329704
33. Bhushal S, Wolfsmüller M, Selvakumar TA, Kemper L, Cell Polarization and Epigenetic Status Shape the Heterogeneous Response to Type III Interferons in Intestinal Epithelial Cells. Front Immunol. 2017;8(June)
34. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M, Biological activity of interleukins-28 and -29: Comparison with type I interferons. Cytokine. 2005;31(2):109–18. doi: 10.1016/j.cyto.2005.04.003 pmid: 15899585
35. Rand U, Rinas M, Werk JS, Nöhren G, Linnes M, Kröger A, et al. Multi-layered stochasticity and paracrine signal propagation shape the type-l interferon response. Mol Syst Biol. 2012;8(584):1–13
36. Maiwald T, Schneider A, Busch H, Sahle S, Gretz N, Weiss TS, et al. Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon-α induced early antiviral signalling. FEBS J. 2010;277(22):4741–54. doi: 10.1111/j.1742-4658.2010.07880.x pmid: 20964804
37. Moraga I, Harari D, Schreiber G, Uze G, Pellegrini S, Receptor Density Is Key to the Alpha2/Beta Interferon Differential Activities. Mol Cell Biol. 2009;29(17):4778–87. doi: 10.1128/MCB.01808-08 pmid: 19564411
38. Levin D, Harari D, Schreiber G, Stochastic Receptor Expression Determines Cell Fate upon Interferon Treatment. Mol Cell Biol. 2011;31(16):3252–66. doi: 10.1128/MCB.05251-11 pmid: 21690295
39. Kalie E, Jaitin DA, Abramovich R, Schreiber G, An interferon ??2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem. 2007;282(15):11602–11. doi: 10.1074/jbc.M610115200 pmid: 17310065
40. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G, The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem. 2008;283(47):32925–36. doi: 10.1074/jbc.M806019200 pmid: 18801736
41. Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, et al. Binding and activity of all human alpha interferon subtypes. Cytokine. 2011;56(2):282–9. doi: 10.1016/j.cyto.2011.07.019 pmid: 21856167
42. Suresh Kumar KG, Barriere H, Carbone CJ, Liu J, Swaminathan G, Xu P, et al. Site-specific ubiquitination exposes a linear motif to promote interferon-α receptor endocytosis. J Cell Biol. 2007;179(5):935–50. doi: 10.1083/jcb.200706034 pmid: 18056411
43. Kumar KGS, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY, SCF HOS ubiquitin ligase mediates the ligand-induced down-regulation of the interferon- a receptor. 2003;22(20)
44. Marijanovic Z, Ragimbeau J, Kumar KGS, Fuchs SY, Pellegrini S, TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem J. 2006;397(1):31–8. doi: 10.1042/BJ20060272 pmid: 16551269
45. Weerd NA De, Samarajiwa SA, Hertzog PJ, Type I Interferon Receptors: Biochemistry and Biological. J Biol Chem. 2007;282(28):20053–7. doi: 10.1074/jbc.R700006200 pmid: 17502368
46. Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, et al. TYK2 and JAK2 Are Substrates of Protein-tyrosine Phosphatase 1B. J Biol Chem. 2001;276(51):47771–4. doi: 10.1074/jbc.C100583200 pmid: 11694501
47. Simoncic PD, Lee-loy A, Barber DL, Tremblay ML, Mcglade CJ, The T Cell Protein Tyrosine Phosphatase Is a Negative Regulator of Janus Family Kinases 1 and 3. Curr Biol. 2002;12(2):446–53
48. Piganis RAR, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, et al. Suppressor of Cytokine Signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon α receptor (IFNAR1)-associated tyrosine kinase tyk2. J Biol Chem. 2011;286(39):33811–8. doi: 10.1074/jbc.M111.270207 pmid: 21757742
49. Malakhov MP, Malakhova OA, Il Kim K, Ritchie KJ, Zhang DE, UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem. 2002;277(12):9976–81. doi: 10.1074/jbc.M109078200 pmid: 11788588
50. Malakhova OA, Kim K Il, Luo J, Zou W, Suresh KG, Fuchs SY, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 2006;25(11):2358–67. doi: 10.1038/sj.emboj.7601149 pmid: 16710296
51. Sarasin-Filipowicz M, Wang X, Yan M, Duong FHT, Poli V, Hilton DJ, et al. Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in the Mouse Liver through Induction of USP18/UBP43. Mol Cell Biol. 2009;29(17):4841–51. doi: 10.1128/MCB.00224-09 pmid: 19564419
52. François-Newton V, de Freitas Almeida GM, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS One. 2011;6(7)
53. Makowska Z, Duong FHT, Trincucci G, Tough DF, Heim MH, Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology. 2011;53(4):1171–80
54. Liu B, Chen S, Guan Y, Chen L, Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients. PLoS One. 2015;10(7):e0133800. doi: 10.1371/journal.pone.0133800 pmid: 26193702
55. Fan W, Xie S, Zhao X, Li N, Chang C, Li L, et al. IFN-λ4 desensitizes the response to IFN-α treatment in chronic hepatitis c through long-term induction of USP18. J Gen Virol. 2016;97(9):2210–20. doi: 10.1099/jgv.0.000522 pmid: 27302182
56. Blumer T, Coto-Llerena M, Duong FHT, Heim MH, SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo. J Biol Chem. 2017;292(43):17928–38. doi: 10.1074/jbc.M117.788877 pmid: 28900038
57. Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, et al. IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol. 2017;ji1700807
58. Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, et al. Protein kinase C-δ (PKC-δ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem. 2002;277(17):14408–16. doi: 10.1074/jbc.M109671200 pmid: 11839738
59. Wieczorek M, Ginter T, Brand P, Heinzel T, Kra OH, Cytokine & Growth Factor Reviews Acetylation modulates the STAT signaling code. 2012;23:293–305
60. Song L, Bhattacharya S, Yunus AA, Lima CD, Schindler C, Stat1 and SUMO modification. Blood. 2017;108(10):3237–45
61. Platanias LC, Fish EN, Signaling pathways activated by interferons. Exp Hematol. 1999;27:1583–92. pmid: 10560905
62. Platanias LC, Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–86. doi: 10.1038/nri1604 pmid: 15864272
63. Lekmine F, Sassano A, Uddin S, Majchrzak B, Miura O, Druker BJ, et al. The CrkL Adapter Protein Is Required for Type I Interferon-Dependent Gene Transcription and Activation of the Small G-Protein Rap1. Biochem Biophys Res Commun. 2002;750:744–50
64. Uddin S, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem. 1999;274(42):30127–31. pmid: 10514501
65. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte J-M, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005;289(5):G960–8. doi: 10.1152/ajpgi.00126.2005 pmid: 16051921
66. Alase A a, El-Sherbiny YM, Vital EM Tobin DJ, Turner N a, Wittmann M, IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. J Invest Dermatol. 2015;(August):1–29
67. Selvakumar TA, Bhushal S, Kalinke U, Wirth D, Hauser H, Köster M, et al. Identification of a predominantly interferon-λ-induced transcriptional profile in murine intestinal epithelial cells. Front Immunol. 2017;8(OCT)
68. Andreakos E, Salagianni M, Galani IE, Koltsida O, Interferon-λs: Front-line guardians of immunity and homeostasis in the respiratory tract. Front Immunol. 2017;8(SEP):1–7
69. Chiriac MT, Buchen B, Wandersee A, Hundorfean G, Günther C, Bourjau Y, et al. Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease. Gastroenterology. 2017;153(1):123–138.e8. doi: 10.1053/j.gastro.2017.03.015 pmid: 28342759
70. Raue A, Kreutz C, Maiwald T, Bachmann J, Schilling M, Klingmüller U, et al. Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Bioinformatics. 2009;25(15):1923–9. doi: 10.1093/bioinformatics/btp358 pmid: 19505944
71. Seber GAF, Wild CJ, Nonlinear Regression. John Wiley & Sons. 2003.775 p